Advertisement.

ROIV Projected Dividend Yield

Ord/Roivant Sciences Ltd ( NASDAQ : ROIV )

Roivant Sciences develops drug candidates in subsidiary companies Co. calls Vants. Co.'s Vants and pipeline include Dermavant Sciences Ltd., which is developing tapinarof for the treatment of psoriasis and atopic dermatitis, with an earlier-stage development pipeline; Immunovant, Inc., which is developing IMVT-1401 for the treatment of Myasthenia Gravis, Warm Autoimmune Hemolytic Anemia and Thyroid Eye Disease; Aruvant Sciences Ltd., which is developing ARU-1801 as a one-time, potentially curative gene therapy for the treatment of sickle cell disease; and Proteovant Sciences, Inc, which is developing heterobifunctional protein degraders for oncology, neurology, and immunology AR Degrader.

20 YEAR PERFORMANCE RESULTS

ROIV Dividend History Detail
ROIV Dividend News
ROIV Competitors News

# of Shares: 0

Closing Price: 11.50

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000